ADPT
Overvalued by 64.9% based on the discounted cash flow analysis.
Market cap | $1.58 Billion |
---|---|
Enterprise Value | $1.58 Billion |
Dividend Yield | $0 (0%) |
Earnings per Share | $-1.08 |
Beta | 1.79 |
Outstanding Shares | 149,195,028 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -10.92 |
---|---|
PEG | 29.38 |
Price to Sales | 10.38 |
Price to Book Ratio | 10.38 |
Enterprise Value to Revenue | 8.34 |
Enterprise Value to EBIT | -11.02 |
Enterprise Value to Net Income | -12 |
Total Debt to Enterprise | 0.03 |
Debt to Equity | 0.29 |
No data
No data
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Adaptive Biotechnologies believes the adap...